HK1251152B - 抗-cd19抗體和布魯頓酪氨酸激酶抑制劑的組合及其用途 - Google Patents

抗-cd19抗體和布魯頓酪氨酸激酶抑制劑的組合及其用途

Info

Publication number
HK1251152B
HK1251152B HK18110551.0A HK18110551A HK1251152B HK 1251152 B HK1251152 B HK 1251152B HK 18110551 A HK18110551 A HK 18110551A HK 1251152 B HK1251152 B HK 1251152B
Authority
HK
Hong Kong
Prior art keywords
bruton
antibody
combination
tyrosine kinase
kinase inhibitor
Prior art date
Application number
HK18110551.0A
Other languages
English (en)
Inventor
Jan Endell
Rainer Boxhammer
Mark Winderlich
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of HK1251152B publication Critical patent/HK1251152B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK18110551.0A 2015-05-26 2018-08-16 抗-cd19抗體和布魯頓酪氨酸激酶抑制劑的組合及其用途 HK1251152B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15169124 2015-05-26
EP15196860 2015-11-27
PCT/EP2016/061744 WO2016189014A1 (en) 2015-05-26 2016-05-25 Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof

Publications (1)

Publication Number Publication Date
HK1251152B true HK1251152B (zh) 2020-04-24

Family

ID=56084030

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18110551.0A HK1251152B (zh) 2015-05-26 2018-08-16 抗-cd19抗體和布魯頓酪氨酸激酶抑制劑的組合及其用途

Country Status (22)

Country Link
US (3) US10617691B2 (zh)
EP (2) EP3302550B1 (zh)
JP (3) JP6916741B2 (zh)
KR (1) KR20180004286A (zh)
CN (2) CN114601931B (zh)
AU (3) AU2016266708B2 (zh)
CA (1) CA2986175A1 (zh)
CY (1) CY1122298T1 (zh)
DK (1) DK3302550T3 (zh)
ES (1) ES2754431T3 (zh)
HK (1) HK1251152B (zh)
HR (1) HRP20192100T1 (zh)
HU (1) HUE046328T2 (zh)
IL (2) IL255377B (zh)
LT (1) LT3302550T (zh)
PL (1) PL3302550T3 (zh)
PT (1) PT3302550T (zh)
RS (1) RS59605B1 (zh)
RU (1) RU2756010C2 (zh)
SI (1) SI3302550T1 (zh)
WO (1) WO2016189014A1 (zh)
ZA (1) ZA201707867B (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107903325B (zh) 2011-05-16 2021-10-29 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
US10870701B2 (en) 2016-03-15 2020-12-22 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
CN110248677B (zh) * 2017-01-05 2023-05-16 上海煦顼技术有限公司 人源化抗cd19抗体及其与嵌合抗原受体的用途
EA202090020A1 (ru) 2017-07-10 2020-04-28 Интернэшнл - Драг - Дивелопмент - Байотек Лечение b-клеточных злокачественных новообразований с использованием афукозилированных проапоптотических анти-cd19 антител в сочетании с анти-cd20 антителами или химиотерапевтическими средствами
EP3847196A4 (en) * 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
KR20200030337A (ko) * 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
WO2022115120A1 (en) * 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
JP2023551519A (ja) * 2020-11-30 2023-12-08 インサイト・コーポレイション 抗ｃｄ１９抗体とパルサクリシブの組み合わせ療法
WO2024037594A1 (en) * 2022-08-19 2024-02-22 Beijing Innocare Pharma Tech Co., Ltd. Combination treatment with orelabrutinib and tafasitamab
KR102655236B1 (ko) 2024-01-02 2024-04-08 한화시스템(주) 빔 조향범위 확장 구조를 가지는 저궤도 통신위성 배열안테나

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
CA2422076A1 (en) 2000-09-18 2002-03-21 Idec Pharmaceutical Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
AU2002357060A1 (en) 2001-12-03 2003-06-17 Abgenix, Inc. Antibody categorization based on binding characteristics
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
EP1648512A4 (en) 2003-07-31 2009-01-21 Immunomedics Inc ANTI-CD19 ANTIBODIES
EP1899379B1 (en) 2005-06-20 2018-04-11 E. R. Squibb & Sons, L.L.C. Cd19 antibodies and their uses
PT1966245E (pt) 2005-12-30 2011-08-31 Merck Patent Gmbh Anticorpos anti-cd19 com imunogenicidade reduzida
ES2457072T3 (es) 2006-08-14 2014-04-24 Xencor, Inc. Anticuerpos optimizados que seleccionan como diana CD19
US8323653B2 (en) 2006-09-08 2012-12-04 Medimmune, Llc Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
DK2081435T3 (en) 2006-09-22 2016-08-15 Pharmacyclics Llc INHIBITORS OF BRUTON'S TYROSINKINASE
DK2176298T3 (en) 2007-05-30 2018-02-12 Xencor Inc Methods and compositions for inhibiting CD32B-expressing cells
PT2211904T (pt) 2007-10-19 2016-11-02 Seattle Genetics Inc Agentes de ligação a cd19 e seus usos
CA2753158A1 (en) 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
CA2765080C (en) 2009-06-24 2018-07-17 The Feinstein Institute For Medical Research Methods for treating chronic lymphocytic leukemia
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
KR101580714B1 (ko) * 2010-06-03 2016-01-04 파마싸이클릭스 엘엘씨 브루톤 티로신 인산화효소(ｂｔｋ)의 억제제의 용도
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
SG194219A1 (en) 2011-06-10 2013-11-29 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
LT2744826T (lt) 2011-08-16 2022-04-25 Morphosys Ag Kombinuota terapija su anti-cd19 antikūnu ir purino analogu
CA3137321A1 (en) * 2011-08-16 2013-02-21 Morphosys Ag Combination therapy with an anti - cd19 antibody and a nitrogen mustard
TWI573792B (zh) * 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
WO2014036016A1 (en) * 2012-08-31 2014-03-06 Principia Biopharma Inc. Benzimidazole derivatives as itk inhibitors
WO2014113932A1 (en) 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors

Also Published As

Publication number Publication date
US10617691B2 (en) 2020-04-14
US20240009196A1 (en) 2024-01-11
PT3302550T (pt) 2019-11-26
IL255377B (en) 2021-12-01
EP3603672A1 (en) 2020-02-05
WO2016189014A1 (en) 2016-12-01
CN107660151B (zh) 2022-03-11
AU2022202796A1 (en) 2022-05-19
IL255377A (en) 2018-02-28
PL3302550T3 (pl) 2020-02-28
RS59605B1 (sr) 2020-01-31
AU2016266708A1 (en) 2017-11-16
SI3302550T1 (sl) 2020-01-31
AU2022202796B2 (en) 2023-11-23
HUE046328T2 (hu) 2020-03-30
ZA201707867B (en) 2021-03-31
CN107660151A (zh) 2018-02-02
HRP20192100T1 (hr) 2020-02-21
JP2018516905A (ja) 2018-06-28
LT3302550T (lt) 2019-11-11
RU2017143166A3 (zh) 2019-11-28
ES2754431T3 (es) 2020-04-17
JP2021152029A (ja) 2021-09-30
EP3302550B1 (en) 2019-08-28
KR20180004286A (ko) 2018-01-10
JP6916741B2 (ja) 2021-08-11
DK3302550T3 (da) 2019-11-04
AU2016266708B2 (en) 2022-02-03
JP2023058502A (ja) 2023-04-25
AU2024201029A1 (en) 2024-03-14
CY1122298T1 (el) 2021-01-27
RU2017143166A (ru) 2019-06-27
IL287433A (en) 2021-12-01
CA2986175A1 (en) 2016-12-01
RU2756010C2 (ru) 2021-09-24
US20180153892A1 (en) 2018-06-07
EP3302550A1 (en) 2018-04-11
US20200206228A1 (en) 2020-07-02
CN114601931A (zh) 2022-06-10
CN114601931B (zh) 2023-09-01

Similar Documents

Publication Publication Date Title
IL287433A (en) Combination of anti-cd19 antibody and proton tyrosine kinase inhibitor and its uses
ZA201903932B (en) Imidazopyrazine inhibitors of bruton's tyrosine kinase
IL255831A (en) Inhibitors of bruton's tyrosine kinase
IL274716A (en) Synthesis of a proton tyrosine kinase inhibitor
ZA201805439B (en) Bruton's tyrosine kinase inhibitors
EP3177366A4 (en) Bruton's tyrosine kinase inhibitor combinations and uses thereof
IL250085A0 (en) New compounds of proton tyrosine kinase inhibitor
IL289766A (en) tfpi inhibitory antibodies and their uses
IL244492A0 (en) Broton tyrosine kinase inhibitors
EP3414234A4 (en) BRUTON TYROSINE KINASE HEMMER
EP3141546A4 (en) Inhibitor of bruton's tyrosine kinase
HK1249736A1 (zh) 布魯頓氏酪氨酸激酶抑制劑的共結晶體
EP3174539A4 (en) Inhibitors of bruton's tyrosine kinase
EP2968341A4 (en) COMBINATIONS OF BURTON TYROSINE KINASE INHIBITORS AND CYP3A4 INHIBITORS
HK1243929A1 (zh) Tlr抑制劑和布魯頓酪氨酸激酶抑制劑組合
ZA201906887B (en) Bruton's tyrosine kinase inhibitors
ZA201903694B (en) Inhibitors of bruton's tyrosine kinase
EP3159340A4 (en) New bruton's tyrosine kinase inhibitor
HK1249737A1 (zh) 布魯頓氏酪氨酸激酶抑制劑的溶劑化形式
IL259862B (en) Inhibitors of proton tyrosine kinase and methods of using them
EP3543239A4 (en) SELECTIVE INHIBITOR OF BRUTON TYROSINE KINASE AND USE THEREOF
EP3328380A4 (en) INHIBITOR COMBINATIONS OF BRUTON TYROSINE KINASE AND USES THEREOF
EP3412657A4 (en) NEW IRREVERSIBLE INHIBITOR OF BRUTON TYROSINE KINASE